What is the challenge EASYGEN addresses?

Only 18% of patients have access to CAR-T therapy. About 30% of total cost-of-care are related to logistics and bridging therapy. Cell therapies often travel across borders twice under tight customs and shipping constraints. Manufacturing depends on manual, error-prone processes with cleanroom-trained technicians. Treatment costs reach over €500,000 per patient, making it unaffordable for many health systems to scale up access.

What is EASYGEN's mission?

EASYGEN's goal is to enable an automated, modular manufacturing platform for CAR-T cell production at the point-of-care. The project aims to reduce treatment cost by 50%, reduce manufacturing time significantly, broaden eligibility for new European patient groups, and embed a platform seamlessly into routine hospital workflows.

EASYGEN: Advancing CAR-T Cell Therapy for cancer in Europe

Paving the way to faster, more accessible CAR-T cell therapies

EASYGEN is a collaborative European public-private research project aiming to optimise CAR-T manufacturing hospital workflows, supporting more scalable access to advanced cell therapies and a sustainable healthcare workforce.

About EASYGEN

EASYGEN Illustration of a CAR-T cell engaging with a cancer cell, representing targeted immunotherapy.

The challenge

Today's CAR-T therapies have a median vein-to-vein time of 3 to 6 weeks. Dependence on specialized, central manufacturing facilities, laborious and cost-intensive workflows, and a complex logistics can limit timely access to these transformative therapies.

Locke FL 2025 Blood Adv.

Only ~18%

of eligible diffuse large B-cell lymphoma (DLBCL) patients across five major European countries receive CAR-T therapy.
Access varies considerably between countries, highlighting that availability of an effective therapy does not automatically translate into patient access.

IQVIA Institute 2025

`About ~30%`

of the total cost of care has been attributed to logistics and bridging therapy in published analyses. Bringing manufacturing closer to patients could reduce parts of this burden.

Silvola S 2022 Value Health

Cross-border complexity

Cell therapies often travel across borders twice, under tight customs and shipping constraints. For an autologous therapy, this means coordinating the movement of both patient cells and the final treatment across a tightly controlled chain of identity and custody.

Resource-intensive

Manufacturing still depends on specialised personnel, infrastructure and multiple high-touch process steps, which can contribute to delays and constrain capacity.

High treatment costs

With overall CAR-T treatment costs potentially exceeding €500,000 per patient, health systems face significant challenges in scaling access.For patients with rapidly progressing disease, time matters: delays during the treatment pathway may mean that some patients deteriorate before they can receive CAR-T therapy.

Senior K 2025 Lancet

Our vision

A future where CAR-T therapies can be manufactured directly in hospitals, using automated, non-viral manufacturing approaches — bringing production closer to patients and helping make advanced cell therapies more accessible and scalable.

Our mission

EASYGEN's (EASY Workflow Integration for GENe Therapy) mission is to help broaden access to advanced cell therapies through the development and evaluation of a scalable, automated, non-viral, point-of-care manufacturing platform that brings CAR-T production closer to the patient.

But technology alone is not enough. EASYGEN brings together manufacturing, quality control, digital integration, hospital workflows, health economics, regulatory considerations and patient perspectives to explore how decentralised CAR-T manufacturing could work in real healthcare environments.

Target a 50% reduction in treatment-related costs.
EASYGEN will evaluate whether decentralised and automated manufacturing can reduce manufacturing, logistics and other treatment-related costs.

Reduce manufacturing time to under 24 hours

Broaden access for more patients

Embed decentralised manufacturing into routine hospital workflows

More about our ambition

For any child or adult needing CAR T-cell therapy, every mile and minute matters.  The distance between patient and lab creates dangerous delays and uncertainty. By moving production into hospitals, the EASYGEN consortium will close that gap, cutting wait times and delivering life-saving therapies faster.

Tom Whitehead from the Emily Whitehead foundation

Tom Whitehead,
 co-founder of the Emily Whitehead Foundation

EASYGEN introduction video

Triangle behind a mountain range made with structural grid like texture

Latest news

First EASYGEN consortium publication accepted in Cytotherapy

The first peer-reviewed EASYGEN consortium perspective examines the barriers limiting CAR-T access in Europe and the potential role of decentralised manufacturing.

Read article

The EASYGEN consortium at their kick off

EASYGEN consortium KickOff

EASYGEN consortium kicks off: Decentralized, automated CAR-T manufacturing moves into the hospital.

Read post

EASYGEN partners

EASYGEN brings together a multidisciplinary European public-private consortium spanning hospitals, academia, research organisations, technology providers, industry and patient organisations.Together, the partners contribute expertise across cell therapy, non-viral gene engineering, automated manufacturing, quality control, digital technologies, health economics, hospital implementation and patient engagement.EASYGEN is coordinated by Fresenius SE & Co. KGaA, with scientific co-leadership from leading European cell-therapy experts.

View our workpackages

Have any questions?  
Just send us a message.

We’d love to hear from you. For questions about EASYGEN, opportunities for scientific exchange, stakeholder engagement or collaboration, please contact us at contact@easygen-consortium.eu

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

This project has received funding from the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101194710. The JU receives support from the European Union’s Horizon Europe research and innovation programme and EFPIA. — Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.

Branding & Website design by Belinda De Bruyn